News Updates
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Read moreIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreOur
Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.
Learn more

